Indication* Product Development Pre-Clinical Clinical Regulatory Market
Lung Cancer PRECIMON
100%
 April-2020
Colorectal Cancer ELAA-002
15%
 Q1-2023
Prostate Cancer ELAA-003
5%
 Q4-2023
* Diagnostic
Regulatory Status | Medical Device Class-II






This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.    OK   Learn More